News about 'TB News'

Botella H, Peyron P, Levillain F, Poincloux R, Poquet Y, Brandli I, Wang C, Tailleux L, Tilleul S, Charrière GM, Waddell SJ, Foti M, Lugo-Villarino G, Gao Q, Maridonneau-Parini I, Butcher PD, Castagnoli PR, Gicquel B, de Chastellier C, Neyrolles O. Mycobacterial p(1)-type ATPases mediate resistance...

Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases. Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development: Diarylquinolines, synthesis pathways and quantitative...

Over the last week, some announcements have been released concerning new tools, publications and meeting materials that may be of value to the TB community including materials from the WGND sponsored “Essentiality of Pyrazinamide” Workshop, an interactive map of clinical trials from PACTR , and a...

Special Focus: Neglected Diseases [PART 1]. Future Medicinal Chemistry. August 2011, Volume 3, Number 10 ( free issue ) Special Focus: Neglected Diseases [PART 2]. Future Medicinal Chemistry. September 2011, Volume 3, Number 11 (not yet released) The August and September issues of Future Medicinal...

Click here for full report The United Nations (UN) released a report on July 12 on the progress made thus far on the 8 Millennium Development Goals (MDGs). The eight MDGs include: end poverty and hunger, universal education, gender equality, child health, maternal health, combat HIV/AIDS,...

Silva RF, Mendonc SCM, Carvalho LM, Reis AM, Gordo I, Trindade S, Dionisio F. Pervasive Sign Epistasis between Conjugative Plasmids and Drug-Resistance Chromosomal Mutations. PLoS Genetics. 2011 July;7(7):1-10. This week we have an article by researchers from Portugal that suggests that in the case...

Recent articles from around the globe related to governments addressing problems with providing treatment services to those with tuberculosis: A Day in the Life of a TB Worker When Farhad Jameel, case manager at Gwinnett County’s tuberculosis control clinic, arrives at work each morning, he...

Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis . 2011 Jul; 15 ( 7 ):949-54. This week, we review a recent...

In the July 7 issue of the New England Journal, two articles and an editorial on latent TB and TB prevention are included: Articles Martinson NA, et al “New regimens to prevent tuberculosis in adults with HIV infection” N Engl J Med 2011; 365: 11-20. Madhi SA, et al “Primary isoniazid prophylaxis...

These are the facts (source: Time to Act-Save a million lives by 2015 brochure ) : At least one out of three people in the world has latent TB infection, which increases the risk of becoming ill with TB. People living with HIV have an estimated 20 to 30 times greater risk of developing active TB...

MIchael D. Iseman Dr. Michael D. Iseman, a world renowned pulmonologist and leading expert on tuberculosis has joined Oxford Immunotec as the Senior Scientific Advisor. To read full story, click here . In May 2010, the WGND had the honor of interviewing Dr. Iseman in our “Voices from the Fight to...

The MTBVAC01 vaccine candidate, developed to protect people against tuberculosis, will start Phase I clinical trials early in 2012. This was announced by the Spanish biopharmaceutical company Biofabri . The candidate was developed by the University of Zaragoza , Spain and is part of the...

Dr. Peter Andersen, the Vice President of Vaccine Research and Development at Statens Serum Institut (SSI) and TBVI partner, has been awarded the prestigious Novo Nordisk prize for his work in TB vaccine development. The WGND interviewed Dr. Andersen for our TB R&D Weekly Update on March 8...

The first detailed study of the private tuberculosis (TB) drug market, published on May 4 th , in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-...

The Stop TB Partnership and the World Health Organization are announcing a call for applications for members to serve on the Global GLC . Deadline for submission of applications is 16 May 2011. A Global GLC Committee (the “gGLC”) is being established that will be 1) a sub-group of the MDR-TB...